These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Liposomal pegylated doxorubicin versus low-dose recombinant interferon Alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers. Kreuter A; Rasokat H; Klouche M; Esser S; Bader A; Gambichler T; Altmeyer P; Brockmeyer NH Cancer Invest; 2005; 23(8):653-9. PubMed ID: 16377582 [TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind study of pegylated liposomal doxorubicin for the treatment of AIDS-related Kaposi's sarcoma. Cooley T; Henry D; Tonda M; Sun S; O'Connell M; Rackoff W Oncologist; 2007 Jan; 12(1):114-23. PubMed ID: 17227906 [TBL] [Abstract][Full Text] [Related]
5. Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma: a retrospective study. Di Lorenzo G; Di Trolio R; Montesarchio V; Palmieri G; Nappa P; Delfino M; De Placido S; Dezube BJ Cancer; 2008 Mar; 112(5):1147-52. PubMed ID: 18098221 [TBL] [Abstract][Full Text] [Related]
6. Low to moderate cumulative doses of pegylated liposomal doxorubicin in the treatment of classic Kaposi sarcoma in elderly patients with comorbidities. Potouridou I; Korfitis C; Ioannidou D; Polydorou D; Zakopoulou N; Stratigos AJ; Katsambas AD Br J Dermatol; 2008 Feb; 158(2):431-2. PubMed ID: 18067475 [No Abstract] [Full Text] [Related]
7. Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma. Amantea MA; Forrest A; Northfelt DW; Mamelok R Clin Pharmacol Ther; 1997 Mar; 61(3):301-11. PubMed ID: 9084455 [TBL] [Abstract][Full Text] [Related]
8. Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery. Lichterfeld M; Qurishi N; Hoffmann C; Hochdorfer B; Brockmeyer NH; Arasteh K; Mauss S; Rockstroh JK; Infection; 2005 Jun; 33(3):140-7. PubMed ID: 15940415 [TBL] [Abstract][Full Text] [Related]
9. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. La-Beck NM; Zamboni BA; Gabizon A; Schmeeda H; Amantea M; Gehrig PA; Zamboni WC Cancer Chemother Pharmacol; 2012 Jan; 69(1):43-50. PubMed ID: 21590446 [TBL] [Abstract][Full Text] [Related]
14. Pegylated liposomal doxorubicin as first line treatment in aids-related Kaposi's sarcoma: a real-life study. Dalu D; Fasola C; Ammoni L; De Francesco D; Cona MS; Rota S; Ferrario S; Gambaro A; Tosca N; Piva S; La Verde N J Chemother; 2021 Sep; 33(5):342-347. PubMed ID: 34060438 [TBL] [Abstract][Full Text] [Related]
15. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma. Duggan ST; Keating GM Drugs; 2011 Dec; 71(18):2531-58. PubMed ID: 22141391 [TBL] [Abstract][Full Text] [Related]
16. Management of AIDS-related Kaposi's sarcoma: advances in target discovery and treatment. Dezube BJ Expert Rev Anticancer Ther; 2002 Apr; 2(2):193-200. PubMed ID: 12113241 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Pegylated Liposomal Doxorubicin-Based Chemotherapy of AIDS-Related Kaposi's Sarcoma: A Meta-Analysis. Liu R; Zhou J; Yang S; Zhang Z Am J Ther; 2018; 25(6):e719-e721. PubMed ID: 29509553 [No Abstract] [Full Text] [Related]
18. Role of pegylated lyposomal doxorubicin (PLD) in systemic Kaposi's sarcoma: a systematic review. Di Trolio R; Di Lorenzo G; Delfino M; De Placido S Int J Immunopathol Pharmacol; 2006; 19(2):253-63. PubMed ID: 16831292 [TBL] [Abstract][Full Text] [Related]
19. Kaposi's sarcoma: DaunoXome approved. AIDS Treat News; 1996 May; (no 246):3-4. PubMed ID: 11363485 [TBL] [Abstract][Full Text] [Related]